<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988922</url>
  </required_header>
  <id_info>
    <org_study_id>201307034</org_study_id>
    <nct_id>NCT01988922</nct_id>
  </id_info>
  <brief_title>CYP2B6 Polymorphisms in Ketamine</brief_title>
  <official_title>Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will determine if genetic variation in CYP2B6 affects how the body
      metabolizes ketamine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The effects of CYP2B6 genetic variants on ketamine metabolism and clearance by CYP2B6*6 hetero or homozygote genotype.</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome will be measured by blood draws taken during the study days and follow-ups.  This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes ketamine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ketamine concentration</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome will be measured by blood and urine collections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>norketamine formation clearances and by genotype</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome will be measured by blood and urine collections.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Ketamine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. oral racemic ketamine 0.4 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>0.4 mg/kg oral racemic ketamine</description>
    <arm_group_label>Ketamine arm</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-50 yr old

          2. CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table)  (Note:  subjects of
             other rare genotype but with one or more 516G&gt;T, 785A&gt;G, 983T&gt;C or 1459C&gt;T
             polymorphism may be enrolled at PI's discretion)

          3. Good general health with no remarkable medical conditions

          4. BMI &lt;33

          5. Provided informed consent

        Exclusion Criteria:

          1. Known history of liver or kidney disease

          2. Use of prescription or non prescription medications, herbals, foods or chemicals
             known to be metabolized by or affecting CYP2B6

          3. Females who are pregnant or nursing

          4. Known history of drug or alcohol addiction (prior or present addiction or treatment
             for addiction)

          5. Direct physical access to and routine handling of addicting drugs in the regular
             course of duty (this is a routine exclusion from studies of drugs with addiction
             potential)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan D Kharach, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Parchomski, RN</last_name>
    <phone>314-747-5164</phone>
    <email>parchomj@anest.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Blood, RN</last_name>
    <phone>314-747-5531</phone>
    <email>bloodj@anest.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Evan D Kharasch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketamine polymorphisms</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
